AAAAAA

   
Results: 1-21 |
Results: 21
QUINUPRISTIN DALFOPRISTIN FOR TREATMENT OF MRSA ENDOCARDITIS REFRACTORY TO CONVENTIONAL THERAPY/
Authors: ANWER S KEEFER MC EVANS TG
Citation: S. Anwer et al., QUINUPRISTIN DALFOPRISTIN FOR TREATMENT OF MRSA ENDOCARDITIS REFRACTORY TO CONVENTIONAL THERAPY/, Infectious diseases in clinical practice, 7(8), 1998, pp. 414-416
IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS
Authors: CLEMENTSMANN ML WEINHOLD K MATTHEWS TJ GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ HSIEH RH MESTECKY J ZOLLAPAZNER S MASCOLA J SCHWARTZ D SILICIANO R COREY L WRIGHT PF BELSHE R DOLIN R JACKSON S XU S FAST P WALKER MC STABLEIN D EXCLER JL TARTAGLIA J DULIEGE AM SINANGIL F PAOLETTI E
Citation: Ml. Clementsmann et al., IMMUNE-RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INDUCEDBY CANARYPOX EXPRESSING HIV-1(MN) GP120, HIV-1(SF2) RECOMBINANT GP120, OR BOTH VACCINES IN SERONEGATIVE ADULTS, The Journal of infectious diseases, 177(5), 1998, pp. 1230-1246
ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES
Authors: GRAHAM BS MCELRATH MJ CONNOR RI SCHWARTZ DH GORSE GJ KEEFER MC MULLIGAN MJ MATTHEWS TJ WOLINSKY SM MONTEFIORI DC VERMUND SH LAMBERT JS COREY L BELSHE RB DOLIN R WRIGHT PF KORBER BT WOLFF MC FAST PE
Citation: Bs. Graham et al., ANALYSIS OF INTERCURRENT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTIONS IN PHASE-I AND PHASE-II TRIALS OF CANDIDATE AIDS VACCINES, The Journal of infectious diseases, 177(2), 1998, pp. 310-319
TH1 TH2 CYTOKINE RESPONSES FOLLOWING HIV-1 IMMUNIZATION IN SERONEGATIVE VOLUNTEERS/
Authors: EVANS TG FITZGERALD T GIBBONS DC KEEFER MC SOUCIER H
Citation: Tg. Evans et al., TH1 TH2 CYTOKINE RESPONSES FOLLOWING HIV-1 IMMUNIZATION IN SERONEGATIVE VOLUNTEERS/, Clinical and experimental immunology, 111(2), 1998, pp. 243-250
ITRACONAZOLE MAINTENANCE TREATMENT FOR HISTOPLASMOSIS IN AIDS - A PROSPECTIVE, MULTICENTER TRIAL
Authors: HECHT FM WHEAT J KORZUN AH HAFNER R SKAHAN KJ LARSEN R LIMJOCO MT SIMPSON M SCHNEIDER D KEEFER MC CLARK R LAI KK JACOBSON JM SQUIRES K BARTLETT JA POWDERLY W
Citation: Fm. Hecht et al., ITRACONAZOLE MAINTENANCE TREATMENT FOR HISTOPLASMOSIS IN AIDS - A PROSPECTIVE, MULTICENTER TRIAL, Journal of acquired immune deficiency syndromes and human retrovirology, 16(2), 1997, pp. 100-107
SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP
Authors: KEEFER MC WOLFF M GORSE GJ GRAHAM BS COREY L CLEMENTSMANN ML VERANIKETTER N ERB S SMITH CM BELSHE RB WAGNER LJ MCELRATH MJ SCHWARTZ DH FAST P CHARRON K REYNOLDS MJ ZIMMERMAN E JONES K HARRIS M FREY SE KENNEDY DJ ISRAEL H BERRY C READ B SPITZ T PACATTE T DOLIN R REICHMAN RC LAMBERT J DEMETER L ROBERTS NJ PUGLIESE M BERGER D BURKE J SCOTT T BLACKSTONE E WRIGHT PF BRAEUNER M RYBCZYK GK CRUMBO K BATTLE W CORNELL R OWENS D JENNINGS M HARBISON MA HENSMAN BJ BARR P STABLEIN DM VOSS T PALLAS S LOMAX N KOFF W LAWRENCE D JOHNSTON M SAVARESE B WESCOTT SL
Citation: Mc. Keefer et al., SAFETY PROFILE OF PHASE-I AND PHASE-II PREVENTIVE HIV TYPE-1 ENVELOPEVACCINATION - EXPERIENCE OF THE NIAID AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 13(14), 1997, pp. 1163-1177
LONGITUDINAL ANALYSIS OF QUANTITATIVE VIROLOGICAL MEASURES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 CD4 LYMPHOCYTES - IMPLICATIONS FOR APPLYING MEASUREMENTS TO INDIVIDUAL PATIENTS
Authors: PAXTON WB COOMBS RW MCELRATH MJ KEEFER MC HUGHES J SINANGIL F CHERNOFF D DEMETER L WILLIAMS B COREY L
Citation: Wb. Paxton et al., LONGITUDINAL ANALYSIS OF QUANTITATIVE VIROLOGICAL MEASURES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 CD4 LYMPHOCYTES - IMPLICATIONS FOR APPLYING MEASUREMENTS TO INDIVIDUAL PATIENTS, The Journal of infectious diseases, 175(2), 1997, pp. 247-254
QUINUPRISTIN DALFOPRISITIN (SYNERCID(R)) FOR THE TREATMENT OF MRSA ENDOCARDITIS REFRACTORY TO VANCOMYCIN/RIFAMPIN/GENTAMICIN THERAPY/
Authors: ANWER S KEEFER MC EVANS TG
Citation: S. Anwer et al., QUINUPRISTIN DALFOPRISITIN (SYNERCID(R)) FOR THE TREATMENT OF MRSA ENDOCARDITIS REFRACTORY TO VANCOMYCIN/RIFAMPIN/GENTAMICIN THERAPY/, Clinical infectious diseases, 23(4), 1996, pp. 174-174
SAFETY AND IMMUNOGENICITY OF ENV-2-3, A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE, IN COMBINATION WITH A NOVEL ADJUVANT, MTP-PEMF59/
Authors: KEEFER MC GRAHAM BS MCELRATH MJ MATTHEWS TJ STABLEIN DM COREY L WRIGHT PF LAWRENCE D FAST PE WEINHOLD K HSIEH RH CHERNOFF D DEKKER C DOLIN R
Citation: Mc. Keefer et al., SAFETY AND IMMUNOGENICITY OF ENV-2-3, A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE, IN COMBINATION WITH A NOVEL ADJUVANT, MTP-PEMF59/, AIDS research and human retroviruses, 12(8), 1996, pp. 683-693
A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE
Authors: GORSE GJ KEEFER MC BELSHE RB MATTHEWS TJ FORREST BD HSIEH RH KOFF WC HANSON CV DOLIN R WEINHOLD KJ FREY SE KETTER N FAST PE
Citation: Gj. Gorse et al., A DOSE-RANGING STUDY OF A PROTOTYPE SYNTHETIC HIV-1(MN) V3 BRANCHED PEPTIDE VACCINE, The Journal of infectious diseases, 173(2), 1996, pp. 330-339
IMMUNIZATION WITH ENVELOPE SUBUNIT VACCINE PRODUCTS ELICITS NEUTRALIZING ANTIBODIES AGAINST LABORATORY-ADAPTED BUT NOT PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: MASCOLA JR SNYDER SW WEISLOW OS BELAY SM BELSHE RB SCHWARTZ DH CLEMENTS ML DOLIN R GRAHAM BS GORSE GJ KEEFER MC MCELRATH MJ WALKER MC WAGNER KF MCNEIL JG MCCUTCHAN FE BURKE DS
Citation: Jr. Mascola et al., IMMUNIZATION WITH ENVELOPE SUBUNIT VACCINE PRODUCTS ELICITS NEUTRALIZING ANTIBODIES AGAINST LABORATORY-ADAPTED BUT NOT PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, The Journal of infectious diseases, 173(2), 1996, pp. 340-348
SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL
Authors: GRAHAM BS KEEFER MC MCELRATH MJ GORSE GJ SCHWARTZ DH WEINHOLD K MATTHEWS TJ ESTERLITZ JR SINANGIL F FAST PE WRIGHT PF DOLIN R COREY L BELSHE RB CLEMENTS ML BOLOGNESI DP STABLEIN DM CHERNOFF D DULIEGE AM WALKER CM
Citation: Bs. Graham et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE HIV-1 VACCINE IN HEALTHY-ADULTS - RECOMBINANT GLYCOPROTEIN (RGP)-120 - A RANDOMIZED, DOUBLE-BLIND TRIAL, Annals of internal medicine, 125(4), 1996, pp. 270
ITRACONAZOLE TREATMENT OF DISSEMINATED HISTOPLASMOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
Authors: WHEAT J HAFNER R KORZUN AH LIMJOCO MT SPENCER P LARSEN RA SIMPSON M SKAHAN KJ KEEFER MC CLARK R LAI KK JACOBSON JM SQUIRES K BARTLETT JA
Citation: J. Wheat et al., ITRACONAZOLE TREATMENT OF DISSEMINATED HISTOPLASMOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME, The American journal of medicine, 98(4), 1995, pp. 336-342
SAFETY PROFILE OF HIV VACCINATION - FIRST 1000 VOLUNTEERS OF AIDS VACCINE EVALUATION GROUP
Authors: KEEFER MC BELSHE R GRAHAM B MCELRATH J CLEMENTS ML SPOSTO R FAST P
Citation: Mc. Keefer et al., SAFETY PROFILE OF HIV VACCINATION - FIRST 1000 VOLUNTEERS OF AIDS VACCINE EVALUATION GROUP, AIDS research and human retroviruses, 10, 1994, pp. 190000139-190000140
STUDIES OF HIGH-DOSES OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GLYCOPROTEIN-160 CANDIDATE VACCINE IN HIV TYPE-1-SERONEGATIVE HUMANS
Authors: KEEFER MC GRAHAM BS BELSHE RB SCHWARTZ D COREY L BOLOGNESI DP STABLEIN DM MONTEFIORI DC MCELRATH MJ CLEMENTS ML GORSE GJ WRIGHT PF MATTHEWS TJ SMITH GE LAWRENCE D DOLIN R
Citation: Mc. Keefer et al., STUDIES OF HIGH-DOSES OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RECOMBINANT GLYCOPROTEIN-160 CANDIDATE VACCINE IN HIV TYPE-1-SERONEGATIVE HUMANS, AIDS research and human retroviruses, 10(12), 1994, pp. 1713-1723
NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1
Authors: BELSHE RB GRAHAM BS KEEFER MC GORSE GJ WRIGHT P DOLIN R MATTHEWS T WEINHOLD K BOLOGNESI DP SPOSTO R STABLEIN DM TWADDELL T BERMAN PW GREGORY T IZU AE WALKER MC FAST P
Citation: Rb. Belshe et al., NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZEDWITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1, JAMA, the journal of the American Medical Association, 272(6), 1994, pp. 475-480
DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING INVACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS
Authors: GRAHAM BS GORSE GJ SCHWARTZ DH KEEFER MC MCELRATH MJ MATTHEWS TJ WRIGHT PF BELSHE RB CLEMENTS ML DOLIN R COREY L BOLOGNESI DP STABLEIN DM ESTERLITZ JR HU SL SMITH GE
Citation: Bs. Graham et al., DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING INVACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS, The Journal of infectious diseases, 170(4), 1994, pp. 782-786
INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS
Authors: BELSHE RB CLEMENTS ML KEEFER MC GRAHAM BS COREY L SPOSTO R WESCOTT S LAWRENCE D GORSE GJ KENNEDY D FREY S LAMBERT J SCHWARTZ D DOLIN R ROBERTS N MCELRATH J COOMBS J WRIGHT P KARZON D FAST P WALKER MC MESTECKY J JACKSON S STABLEIN D WOLFF M
Citation: Rb. Belshe et al., INTERPRETING HIV SERODIAGNOSTIC TEST-RESULTS IN THE 1990S - SOCIAL RISKS OF HIV VACCINE STUDIES IN UNINFECTED VOLUNTEERS, Annals of internal medicine, 121(8), 1994, pp. 584
PERSISTING HIV-1 GP160-SPECIFIC HUMAN T-LYMPHOCYTE RESPONSES AFTER RECEIPT OF VACCINIA RECOMBINANT AND PURIFIED SUBUNIT HIV-DERIVED ENVELOPE VACCINES
Authors: ELDAHER N KEEFER MC REICHMAN RC DOLIN R ROBERTS NJ
Citation: N. Eldaher et al., PERSISTING HIV-1 GP160-SPECIFIC HUMAN T-LYMPHOCYTE RESPONSES AFTER RECEIPT OF VACCINIA RECOMBINANT AND PURIFIED SUBUNIT HIV-DERIVED ENVELOPE VACCINES, AIDS research and human retroviruses, 9, 1993, pp. 190000079-190000079
SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION
Authors: BELSHE RB CLEMENTS ML DOLIN R GRAHAM BS MCELRATH J GORSE GJ SCHWARTZ D KEEFER MC WRIGHT P COREY L BOLOGNESI DP MATTHEWS TJ STABLEIN DM OBRIEN FS EIBL M DORNER F KOFF W
Citation: Rb. Belshe et al., SAFETY AND IMMUNOGENICITY OF A FULLY GLYCOSYLATED RECOMBINANT GP160 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VACCINE IN SUBJECTS AT LOW-RISK OF INFECTION, The Journal of infectious diseases, 168(6), 1993, pp. 1387-1395
PERSISTING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP160-SPECIFIC HUMAN T-LYMPHOCYTE RESPONSES INCLUDING CD8+ CYTOTOXIC ACTIVITY AFTER RECEIPT OF ENVELOPE VACCINES
Authors: ELDAHER N KEEFER MC REICHMAN RC DOLIN R ROBERTS NJ
Citation: N. Eldaher et al., PERSISTING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP160-SPECIFIC HUMAN T-LYMPHOCYTE RESPONSES INCLUDING CD8+ CYTOTOXIC ACTIVITY AFTER RECEIPT OF ENVELOPE VACCINES, The Journal of infectious diseases, 168(2), 1993, pp. 306-313
Risultati: 1-21 |